利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.019 秒)

    QUINOXALINYL DERIVATIVES
    2.
    发明公开
    QUINOXALINYL DERIVATIVES 审中-公开
    喹喔啉衍生物

    公开(公告)号：EP2222161A1

    公开(公告)日：2010-09-01

    申请号：EP08857081.7

    申请日：2008-12-03

    申请人： Enanta Pharmaceuticals, Inc.

    发明人： NIU, Deqiang ,  LIU, Dong ,  MOORE, Joel, D. ,  XU, Guoyou ,  SUN, Ying ,  GAI, Yonghua ,  TANG, Datong ,  OR, Yat, Sun ,  WANG, Zhe

    IPC分类号： A01N41/06 ,  A01N57/00 ,  A61K31/18

    CPC分类号： C07D487/04 ,  A61K38/212 ,  A61K38/215 ,  C07K5/06165 ,  C07K5/0812 ,  A61K2300/00

    摘要： The present invention relates to compounds of Formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译： 本发明涉及式（I）或（II）的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。 本发明进一步涉及包含前述化合物的药物组合物，用于给予患有HCV感染的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    6,11 BICYCLIC ERYTHROMYCIN DERIVATIVES
    4.
    发明公开
    6,11 BICYCLIC ERYTHROMYCIN DERIVATIVES 审中-公开
    6,11 BIZYKLISCHE ERYTHROMYCINDERIVATE

    公开(公告)号：EP1509538A1

    公开(公告)日：2005-03-02

    申请号：EP03726818.2

    申请日：2003-05-13

    申请人： Enanta Pharmaceuticals, Inc.

    发明人： OR, Yat, Sun ,  WANG, Guoqiang ,  PHAN, Ly, Tam ,  NIU, Deqiang ,  QUI, Yao-Ling ,  VO, Nha, Huu ,  FARMER, Jay, Judson ,  HOU, Ying

    IPC分类号： C07H17/00 ,  A61K31/00

    CPC分类号： C07H17/08

    摘要： The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

    MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
    7.
    发明公开
    MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS 审中-公开
    咪唑啉酮类抗生素C蛋白酶

    公开(公告)号：EP2037947A2

    公开(公告)日：2009-03-25

    申请号：EP07812038.3

    申请日：2007-06-06

    申请人： Enanta Pharmaceuticals, Inc.

    发明人： SUN, Ying ,  NIU, Deqiang ,  XU, Guoyou ,  OR, Yat, Sun ,  WANG, Zhe

    IPC分类号： A61K38/12

    CPC分类号： A61K38/212 ,  A61K38/12 ,  A61K38/215 ,  C07K5/0804 ,  A61K2300/00

    摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.